PFIZER INC (PFE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PFE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PFE | Director; Committee Member | 66 | ["Business Leadership & Operations","Finance & Accounting","Risk Management","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Compensation","Audit Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WRB | Founder and Managing Partner of GenNx360 Capital Partners, founder and former Chairman and Chief Executive Officer of Blaylock & Company, Inc.; Committee Member | 66 | ["1 current (Pfizer Inc.)","2 former (CarMax, Inc., Advantage Solutions Inc.)","Founder and Managing Partner of GenNx360 Capital Partners","Former Chairman and CEO of Blaylock & Company, Inc.","Senior management positions with PaineWebber Group and Citicorp","Board of Directors / Senior Leadership Experience","Start-ups/Entrepreneurial","Human Capital Management/ Compensation","Governance, Regulatory & Public Policy","Sustainability Management","Technology"] | ["Business Ethics","Compensation","Nominating and Corporate Governance","Audit"] | 2026 |
| ADV | Director | 62 | [] | [] | 2022 |
| KMX | Founder and Managing Partner of GenNx360 Capital Partners, a private-equity buyout fund | 57 | ["Founder and Managing Partner of GenNx360 Capital Partners","Chief Executive Officer of Blaylock & Company","Experience with PaineWebber and Citigroup"] | ["Compensation and Personnel"] | 2017 |
Biography sourced from the proxy statement filing.
Ronald E. Blaylock is a distinguished business leader and financial expert who currently serves as a Director at Pfizer Inc. As an independent board member, Blaylock brings a wealth of experience and knowledge to the company. He has been a part of Pfizer's board since 2017, contributing to the company's growth and success through his strategic insights and leadership.
Blaylock's professional background is marked by his extensive experience in finance and business leadership. He is the founder and CEO of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies. Prior to founding GenNx360, Blaylock served as a Managing Director at UBS and held various leadership positions at other prominent financial institutions, including Bear Stearns and Citicorp. His expertise in finance and business operations has been instrumental in guiding Pfizer's strategic decisions and ensuring the company's financial stability.
At Pfizer, Ronald E. Blaylock serves on the Audit Committee, leveraging his skills in finance and accounting to provide valuable oversight and guidance. He is also recognized as an Audit Committee Financial Expert, further highlighting his proficiency in financial matters. Blaylock's role on the board extends beyond the Audit Committee, as he actively participates in discussions related to risk management and overall business leadership. His independent perspective and deep understanding of the industry have made him an invaluable asset to Pfizer, helping the company navigate complex challenges and seize new opportunities in the ever-evolving pharmaceutical landscape.